Skip to main content
. Author manuscript; available in PMC: 2020 Jul 29.
Published in final edited form as: Curr Atheroscler Rep. 2020 Jun 18;22(8):35. doi: 10.1007/s11883-020-00852-w

Table 1.

Coronary microvascular dysfunction (CMD) treatment options

Abnormal coronary vasoconstriction or endothelial inflammation
 Angiotensin-converting enzyme inhibitors (ACE-I)
 HMG-CoA reductase inhibitors (statins)
 L-Arginine supplementation
 Aerobic exercise
 Enhanced external counterpulsation (EECP)
Abnormal coronary vasodilation
 Beta-blockers/alpha-beta-blockers
 Nitrates
Anti-anginal
 Ranolazine
 Ivabradine
 Xanthine derivatives
Abnormal smooth muscle function (Prinzmetal’s angina)
 Calcium channel blockers
 Nitrates
Abnormal cardiac nociception
 Low-dose tricyclic medication
 Spinal cord stimulation
 Cognitive behavioral therapy